Targeting CD44 in mast cell regulation

By Tanaka Satoshi  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 1, 2010-01 ,pp. : 31-43

Informa Healthcare

Access to resources Recommend Favorite

PIP3 Regulation as Promising Targeted Therapy of Mast-Cell-Mediated Diseases

By  

Current Pharmaceutical Design, Vol. 17, Iss. 34, 2011-11 ,pp. : 3815-3822

Bentham Science Publishers

Access to resources Recommend Favorite

Vitamin-mediated immune regulation in the development of inflammatory diseases

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 15, Iss. 3, 2015-01 ,pp. : 212-215

Bentham Science Publishers

Access to resources Recommend Favorite

N-(2-Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation

By Mazzari S.   Canella R.   Petrelli L.   Marcolongo G.   Leon A.  

European Journal of Pharmacology, Vol. 300, Iss. 3, 1996-04 ,pp. : 227-236

Elsevier

Access to resources Recommend Favorite

Mast Cells in Allergic and Inflammatory Diseases

By  

Current Pharmaceutical Design, Vol. 18, Iss. 16, 2012-06 ,pp. : 2261-2277

Bentham Science Publishers

Access to resources Recommend Favorite